Inclusion Criteria:

- Aged ≥18 years old, regardless of gender;

- There is a history of novel coronavirus antigen- or nucleic acid-positive infection
within 1-2 weeks;

- HRCT is consistent with the manifestation of viral pneumonia (judged by the
investigator)

- Participants who voluntarily sign informed consent.

Exclusion Criteria:

- Participants who cannot take orally, or are suspected to be allergic to Jaktinib
hydrochloride, similar drugs, or their excipients, or have severe gastrointestinal
dysfunction that affects drug absorption;

- Critical pneumonia Participants with other organ failure requiring ICU monitoring
and treatment;

- Participants who have received the following treatments within the specified time
window before randomization:

1. Participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6)
inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B
cell depletion agent, interferon and other immunosuppressive drugs within the
first two weeks of randomization, except glucocorticoid;

2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first
five drug half-lives at random;

- Immune deficiency;

- Participants who have received the novel coronavirus vaccine within 1 week before
randomization;

- Prior to randomization, there were the following active and uncontrolled infections:
tuberculosis, HIV, syphilis, mycoplasma, chlamydia, parasites, and viral infections
other than SARS CoV-2 that required systemic anti-infection treatment;

- Renal diseases requiring dialysis treatment;

- Pregnant and lactating women;

- Any other Participants that were considered unsuitable by the investigator.